Company: BNBX
Filing Date: 2025-10-30
Form Type: S-1
Source: 0001104659-25-103871
Chunk: 200

Company: BNB PLUS CORP.
Filing Date: 2025-10-30
Form: S-1
Chunk 200
---
 Applied DNA Clinical Labs LLC is not a Material Subsidiary.

<div align='center'>F-44</div>

NOTE E — CAPITAL STOCK, continued Amendment to May 2024 Series A Warrants, continued In connection with the October Registered Direct Offering, the Price Reset Mechanism in the May 2024 Series A Warrants was triggered, which resulted in the number of shares of common stock issuable upon exercise of the May 2024 Series A Warrants increasing from 12,308to 122,521. The exercise price of the May 2024 Series A Warrants was adjusted from $ 1,492.50per share to $ 150.00per share with the respect to the May 2024 Series A Warrants amended by the Warrant Amendment and to $ 141.75with respect to the May 2024 Series A Warrants not amended by the Warrant Amendment. As a result of the March 2025 Reverse Stock Split, the exercise Price Reset Mechanism was triggered for the May 2024 Series A Warrants, which resulted in the number of shares of common stock issuable upon exercise of the May 2024 Series A Warrants increasing from 122,521to 655,676. The exercise price of the May 2024 Series A Warrants was adjusted from $ 150.00per share for the amended May 2024 Series A Warrants and $ 141.75per share for the May 2024 Series A Warrants that were not amended to $ 26.91per share for all of the May 2024 Series A warrants. As a result of the June 2025 Reverse Stock Split, the exercise Price Reset Mechanism was triggered for the May 2024 Series A Warrants, which resulted in the number of shares of common stock issuable upon exercise of the May 2024 Series A Warrants increasing from 626,555to 3,286,016. The exercise price of the May 2024 Series A Warrants was adjusted from $ 26.91per share to $ 5.13per share. May 2024 Series B Warrants Price and Share Adjustment As a result of the March 2025 Reverse Stock Split, the exercise Price Reset Mechanism was triggered for the May 2024 Series B Warrants, which resulted in the number of shares of common stock issuable upon exercise of the May 2024 Series B Warrants increasing from 3,009to 163,019.